Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma
Treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC) patients remain limited, meaning that death within weeks of diagnosis unfortunately remains a common occurrence. Whilst metastases from other malignancy sites, such as colorectal and breast, are amenable to resection in select...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Clinical Surgical Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2773160X23000120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846160283380219904 |
|---|---|
| author | James M. Halle-Smith Lewis A. Hall Sarah F. Powell-Brett Nabeel Merali Adam Frampton Keith J. Roberts |
| author_facet | James M. Halle-Smith Lewis A. Hall Sarah F. Powell-Brett Nabeel Merali Adam Frampton Keith J. Roberts |
| author_sort | James M. Halle-Smith |
| collection | DOAJ |
| description | Treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC) patients remain limited, meaning that death within weeks of diagnosis unfortunately remains a common occurrence. Whilst metastases from other malignancy sites, such as colorectal and breast, are amenable to resection in selected patients, consensus remains largely against resection of mPDAC. Without surgical resection, chemotherapy remains the main treatment option and despite advances in regimens, a large proportion of mPDAC patients do not respond to these treatments. Understandably, investigation into whether different genetic subtypes of PDAC can explain the changes in response to chemotherapy have been carried out but as yet has not demonstrated any marked differences between those that do and do not respond to chemotherapy treatment.This review outlines the emerging role that both the gut and tumour microbiome play in modulating the progression of PDAC, ranging from chemosensitivity to immune infiltration of the tumour This puts the gut microbiome in a promising position as a potential future therapeutic route for mPDAC patients. Possible methods to modulate the gut and tumour microbiome include antibiotics, probiotics and faecal microbiota transplantation (FMT). The next steps should therefore be to focus upon how we can effectively and safely introduce these beneficial bacteria into the gut and tumour microbiome of mPDAC patients through clinical trials. |
| format | Article |
| id | doaj-art-bf8dbe178f2c4e8ab35a9ead5250df50 |
| institution | Kabale University |
| issn | 2773-160X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Surgical Oncology |
| spelling | doaj-art-bf8dbe178f2c4e8ab35a9ead5250df502024-11-22T07:40:08ZengElsevierClinical Surgical Oncology2773-160X2023-12-0124100020Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinomaJames M. Halle-Smith0Lewis A. Hall1Sarah F. Powell-Brett2Nabeel Merali3Adam Frampton4Keith J. Roberts5Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; Corresponding author. James M Halle-Smith Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; College of Medical and Dental Sciences, University of Birmingham, Birmingham, United KingdomHepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; College of Medical and Dental Sciences, University of Birmingham, Birmingham, United KingdomSection of Oncology, Dept. of Clinical & Experimental Medicine, University of Surrey, Guildford, Surrey, United Kingdom; Minimal Access Therapy Training Unit (MATTU), Leggett Building, University of Surrey, Guildford, Surrey, United Kingdom; Department of Hepato-Pancreato-Biliary (HPB) Surgery, Royal Surrey County Hospital, Egerton Road, Guildford, Surrey, United KingdomSection of Oncology, Dept. of Clinical & Experimental Medicine, University of Surrey, Guildford, Surrey, United Kingdom; Minimal Access Therapy Training Unit (MATTU), Leggett Building, University of Surrey, Guildford, Surrey, United Kingdom; Department of Hepato-Pancreato-Biliary (HPB) Surgery, Royal Surrey County Hospital, Egerton Road, Guildford, Surrey, United KingdomHepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; College of Medical and Dental Sciences, University of Birmingham, Birmingham, United KingdomTreatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC) patients remain limited, meaning that death within weeks of diagnosis unfortunately remains a common occurrence. Whilst metastases from other malignancy sites, such as colorectal and breast, are amenable to resection in selected patients, consensus remains largely against resection of mPDAC. Without surgical resection, chemotherapy remains the main treatment option and despite advances in regimens, a large proportion of mPDAC patients do not respond to these treatments. Understandably, investigation into whether different genetic subtypes of PDAC can explain the changes in response to chemotherapy have been carried out but as yet has not demonstrated any marked differences between those that do and do not respond to chemotherapy treatment.This review outlines the emerging role that both the gut and tumour microbiome play in modulating the progression of PDAC, ranging from chemosensitivity to immune infiltration of the tumour This puts the gut microbiome in a promising position as a potential future therapeutic route for mPDAC patients. Possible methods to modulate the gut and tumour microbiome include antibiotics, probiotics and faecal microbiota transplantation (FMT). The next steps should therefore be to focus upon how we can effectively and safely introduce these beneficial bacteria into the gut and tumour microbiome of mPDAC patients through clinical trials.http://www.sciencedirect.com/science/article/pii/S2773160X23000120Pancreatic ductal adenocarcinomaMetastasesGut microbiomeTumour microbiome |
| spellingShingle | James M. Halle-Smith Lewis A. Hall Sarah F. Powell-Brett Nabeel Merali Adam Frampton Keith J. Roberts Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma Clinical Surgical Oncology Pancreatic ductal adenocarcinoma Metastases Gut microbiome Tumour microbiome |
| title | Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma |
| title_full | Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma |
| title_fullStr | Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma |
| title_full_unstemmed | Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma |
| title_short | Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma |
| title_sort | realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma |
| topic | Pancreatic ductal adenocarcinoma Metastases Gut microbiome Tumour microbiome |
| url | http://www.sciencedirect.com/science/article/pii/S2773160X23000120 |
| work_keys_str_mv | AT jamesmhallesmith realisingthetherapeuticpotentialofthehumanmicrobiotainmetastaticpancreaticductaladenocarcinoma AT lewisahall realisingthetherapeuticpotentialofthehumanmicrobiotainmetastaticpancreaticductaladenocarcinoma AT sarahfpowellbrett realisingthetherapeuticpotentialofthehumanmicrobiotainmetastaticpancreaticductaladenocarcinoma AT nabeelmerali realisingthetherapeuticpotentialofthehumanmicrobiotainmetastaticpancreaticductaladenocarcinoma AT adamframpton realisingthetherapeuticpotentialofthehumanmicrobiotainmetastaticpancreaticductaladenocarcinoma AT keithjroberts realisingthetherapeuticpotentialofthehumanmicrobiotainmetastaticpancreaticductaladenocarcinoma |